How PBMs Are Driving Up Prescription Drug Costs

The rising cost of prescription drugs has become a major concern for Americans, with many struggling to afford the medications they need to manage their health. While there are many factors contributing to this issue, one often overlooked culprit is Pharmacy Benefit Managers (PBMs). PBMs are companies that act as intermediaries between pharmacies, drug manufacturers, and health insurance companies, but their practices are driving up prescription drug costs and putting profits over patients.

What are PBMs?

PBMs were originally created to help manage prescription drug benefits for health insurance companies and self-insured employers. They were intended to negotiate discounts with drug manufacturers, process claims, and manage pharmacy networks. However, over time, PBMs have evolved into powerful middlemen that exert significant control over the prescription drug supply chain.

How PBMs Drive Up Costs

PBMs use several tactics to drive up prescription drug costs, including:

1. Rebates and Kickbacks: PBMs negotiate rebates with drug manufacturers in exchange for preferential treatment on their formularies (lists of approved drugs). These rebates can be substantial, but they are not always passed on to consumers. Instead, PBMs keep the rebates as profit, driving up the cost of drugs for patients.
2. Spread Pricing: PBMs charge health insurance companies and self-insured employers a higher price for drugs than they pay to pharmacies. This “spread” is kept as profit by the PBM, increasing the cost of drugs for patients.
3. Mail-Order Pharmacy Mandates: PBMs often require patients to use their own mail-order pharmacies, which can lead to higher costs and lower quality care. These mandates can also limit patient choice and access to local pharmacies.
4. Formulary Management: PBMs create formularies that favor more expensive drugs over cheaper alternatives. This can lead to higher costs for patients and health insurance companies.
5. Administrative Fees: PBMs charge pharmacies and health insurance companies administrative fees for services such as claims processing and network management. These fees can be substantial and drive up the cost of drugs.

The Impact on Patients

The practices of PBMs have a significant impact on patients, including:

1. Higher Out-of-Pocket Costs: Patients are forced to pay higher out-of-pocket costs for their medications, which can lead to non-adherence and poor health outcomes.
2. Limited Access to Care: PBMs’ formulary management and mail-order pharmacy mandates can limit patient access to certain drugs and pharmacies, reducing their ability to receive quality care.
3. Reduced Transparency: PBMs’ complex business practices and lack of transparency make it difficult for patients to understand the true cost of their medications.

Reforming the System

To address the issue of rising prescription drug costs, policymakers and regulators must take action to reform the PBM system. This can be achieved through:

1. Increased Transparency: PBMs should be required to disclose their business practices, including rebates, spread pricing, and administrative fees.
2. Regulatory Oversight: Regulators should be given the authority to monitor and regulate PBM practices to ensure they are acting in the best interests of patients.
3. Patient Protections: Policymakers should implement patient protections, such as prohibiting gag clauses that prevent pharmacists from disclosing lower-cost options to patients.
4. Promoting Competition: Encouraging competition in the PBM market can help drive down costs and improve services.

Conclusion

The rising cost of prescription drugs is a complex issue with many contributing factors. However, the practices of PBMs are a significant driver of these costs, and reform is needed to protect patients and promote affordable access to care. By increasing transparency, regulatory oversight, and patient protections, we can create a more equitable and sustainable prescription drug system that puts patients over profits.